Trial ID or NCT#

NCT02477696

Status

not recruiting iconNOT RECRUITING

Purpose

This research study is evaluating an investigational drug, called ACP-196, in comparison with a drug called ibrutinib as a possible treatment for patients with CLL. The purpose of this study, which involves research, is to determine if an experimental drug: ACP-196 is safe and effective in the treatment of this disease.

Official Title

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Caroline Berube
Caroline Berube
Hematologist
Clinical Associate Professor, Medicine - Hematology
Rondeep Brar
Rondeep Brar
Hematologist, Leukemia specialist, Medical oncologist
Clinical Associate Professor, Medicine - Hematology
Steven Coutre
Steven Coutre
Hematologist, Leukemia specialist
David Iberri
David Iberri
Hematologist, Medical oncologist
Clinical Assistant Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061